The European Tribune is a forum for thoughtful dialogue of European and international issues. You are invited to post comments and your own articles.
Please REGISTER to post.
ScienceDaily (Feb. 9, 2012) -- Neuroscientists at Case Western Reserve University School of Medicine have made a dramatic breakthrough in their efforts to find a cure for Alzheimer's disease. The researchers' findings, published in the journal Science, show that use of a drug in mice appears to quickly reverse the pathological, cognitive and memory deficits caused by the onset of Alzheimer's. The results point to the significant potential that the medication, bexarotene, has to help the roughly 5.4 million Americans suffering from the progressive brain disease. Bexarotene has been approved for the treatment of cancer by the U.S. Food and Drug Administration for more than a decade. These experiments explored whether the medication might also be used to help patients with Alzheimer's disease, and the results were more than promising. Alzheimer's disease arises in large part from the body's inability to clear naturally-occurring amyloid beta from the brain. In 2008 Case Western Reserve researcher Gary Landreth, PhD, professor of neurosciences, discovered that the main cholesterol carrier in the brain, Apolipoprotein E (ApoE), facilitated the clearance of the amyloid beta proteins. Landreth, a professor of neurosciences in the university's medical school, is the senior author of this study as well.
ScienceDaily (Feb. 9, 2012) -- Neuroscientists at Case Western Reserve University School of Medicine have made a dramatic breakthrough in their efforts to find a cure for Alzheimer's disease. The researchers' findings, published in the journal Science, show that use of a drug in mice appears to quickly reverse the pathological, cognitive and memory deficits caused by the onset of Alzheimer's. The results point to the significant potential that the medication, bexarotene, has to help the roughly 5.4 million Americans suffering from the progressive brain disease.
Bexarotene has been approved for the treatment of cancer by the U.S. Food and Drug Administration for more than a decade. These experiments explored whether the medication might also be used to help patients with Alzheimer's disease, and the results were more than promising.
Alzheimer's disease arises in large part from the body's inability to clear naturally-occurring amyloid beta from the brain. In 2008 Case Western Reserve researcher Gary Landreth, PhD, professor of neurosciences, discovered that the main cholesterol carrier in the brain, Apolipoprotein E (ApoE), facilitated the clearance of the amyloid beta proteins. Landreth, a professor of neurosciences in the university's medical school, is the senior author of this study as well.
by JakeS - May 15 7 comments
by Nomad - May 10 14 comments
by Metatone - May 14 84 comments
by ARGeezer - May 16 10 comments
by DoDo - May 12 10 comments
by Migeru - May 6 100 comments
by Migeru - May 7 8 comments
by marco - May 7 82 comments
by gmoke - May 17
by ARGeezer - May 1610 comments
by JakeS - May 157 comments
by Metatone - May 1484 comments
by DoDo - May 1210 comments
by Nomad - May 1014 comments
by Migeru - May 78 comments
by marco - May 782 comments
by Migeru - May 6100 comments
by Ted Welch - May 35 comments
by afew - May 340 comments
by ceebs - May 26 comments
by gmoke - Apr 301 comment
by Frank Schnittger - Apr 3067 comments
by joelado - Apr 2954 comments
by Metatone - Apr 2854 comments
by ATinNM - Apr 275 comments
by ceebs - Apr 265 comments
by Frank Schnittger - Apr 2686 comments
by In Wales - Apr 2136 comments